Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Terminated 3Completed 3Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 13Dermatologic 3CNS 3Thoracic 2Plasma cell 2Head & Neck 2Gastrointestinal 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1Endocrine 1Classical hematology 1Breast 1

Conditions

Melanoma 2Skin Neoplasms 1Carcinoma, Merkel Cell 1

Interventions

pembrolizumab 58Ipilimumab 53Cyclophosphamide 53Nivolumab 45aldesleukin 35Interleukin-2 26fludarabine phosphate 22fludarabine 21Vemurafenib 20Temozolomide 19Radiotherapy 19dabrafenib 15trametinib 12Radiosurgery 11CTLA-4 Antigen 11spartalizumab 10Filgrastim 10Dacarbazine 10cobimetinib 9binimetinib 9atezolizumab 9Biopsy 9poly ICLC 8Paclitaxel 8Antilymphocyte Serum 8encorafenib 7avelumab 7Rituximab 7Introns 7romidepsin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × cabozantinib × Dermatologic × Clear all
NCT05200143 2024-09-19

Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma

Providence Health & Services

Phase 2 Terminated
4 enrolled 11 charts
Dermatologic

Melanoma

NCT02036476 2023-05-09

Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma

Dana-Farber Cancer Institute

Phase 2 Terminated
8 enrolled 7 charts
Dermatologic

Skin Neoplasms, Carcinoma, Merkel Cell

NCT01835184 2014-09-25

Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 1 Terminated
5 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡